Zeiner et al., 2019 - Google Patents
Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patientsZeiner et al., 2019
View HTML- Document ID
- 2933031353234207236
- Author
- Zeiner P
- Kinzig M
- Divé I
- Maurer G
- Filipski K
- Harter P
- Senft C
- Bähr O
- Hattingen E
- Steinbach J
- Sörgel F
- Voss M
- Steidl E
- Ronellenfitsch M
- Publication year
- Publication venue
- Journal of Clinical Medicine
External Links
Snippet
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this …
- 239000002138 L01XE21 - Regorafenib 0 title abstract description 146
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zeiner et al. | Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients | |
Rosar et al. | Efficacy and safety of [225Ac] Ac-PSMA-617 augmented [177Lu] Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis | |
Castello et al. | Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors | |
Apostolidis et al. | Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3) | |
Bumes et al. | Non-invasive prediction of IDH mutation in patients with glioma WHO II/III/IV based on F-18-FET PET-guided in vivo 1H-magnetic resonance spectroscopy and machine learning | |
Khreish et al. | Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy | |
Khreish et al. | Value of combined PET imaging with [18F] FDG and [68Ga] Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu] Lu-PSMA-617 RLT | |
Kazerouni et al. | Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer | |
Laakmann et al. | Radiological patterns of brain metastases in breast cancer patients: a subproject of the german brain metastases in breast cancer (BMBC) registry | |
Shen et al. | Biphasic mathematical model of cell–drug interaction that separates target-specific and off-target inhibition and suggests potent targeted drug combinations for multi-driver colorectal cancer cells | |
Pijnappel et al. | Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer | |
Lang et al. | First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes | |
Galijasevic et al. | Magnetic resonance spectroscopy in diagnosis and follow-up of gliomas: State-of-the-Art | |
Mahdal et al. | New target for precision medicine treatment of giant-cell tumor of bone: sunitinib is effective in the treatment of neoplastic stromal cells with activated PDGFRβ signaling | |
Kim et al. | Therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, based on diagnostic biomarker test in MET-addicted cancer | |
Würtemberger et al. | Diffusion microstructure imaging to analyze perilesional T2 signal changes in brain metastases and glioblastomas | |
Saeki et al. | Skeletal muscle volume is an independent predictor of survival after sorafenib treatment failure for hepatocellular carcinoma | |
Mazibuko et al. | Subacute changes in N-acetylaspartate (NAA) following ischemic stroke: A serial MR spectroscopy pilot study | |
Boerrigter et al. | RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer | |
Chiocchi et al. | Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab | |
Chung et al. | Radiation-induced metabolic shifts in the hepatic parenchyma: findings from 18F-FDG PET imaging and tissue NMR metabolomics in a mouse model for hepatocellular carcinoma | |
Gerritse et al. | High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors | |
Sirico et al. | Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer | |
Lee et al. | Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin | |
Miedema et al. | 89Zr-Immuno-PET with immune checkpoint inhibitors: measuring target engagement in healthy organs |